Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster - Wikidata - awgldk - TriplyDB

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

http://www.wikidata.org/entity/Q37171211

about

Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Novel approaches and challenges to treatment of central nervous system viral infections What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Herpes zoster and postherpetic neuralgia in older adults Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Herpes Zoster and Recurrent Herpes Zoster Adverse events in IBD: to stop or continue immune suppressant and biologic treatment Herpes zoster: diagnostic, therapeutic, and preventive approaches.Risk of infections associated with biological treatment in inflammatory bowel disease.Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.Restoration of Wnt/β-catenin signaling attenuates alcoholic liver disease progression in a rat model.Infection Risk and Safety of Corticosteroid Use.Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study.Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.Adverse effects of golimumab in the treatment of rheumatologic diseases.Infectious and malignant complications of TNF inhibitor therapy in IBD.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.Vaccinating the inflammatory bowel disease patient.Vaccination of patients with autoimmune inflammatory rheumatic diseases.Safety issues and concerns of new immunomodulators in rheumatology.Nontuberculous mycobacteria infections in immunosuppressed hosts.Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study.Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010.Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy.The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service - Sample cohort database.

P2860

Q26781940-1034581A-992C-42C9-8431-EAD986410BB0 Q26825440-E82BB0B3-5CA2-444A-ADE9-A9395BBE5F7A Q26859134-F32D65B5-DE8E-4291-A8DD-5809FCCF7499 Q26862449-A39B5FB2-E35C-43EB-8520-08E74B32D4CC Q27687191-989A1AB1-3B44-47E7-B2E8-CD0A81530DC5 Q28074148-78DE68A6-8236-4558-BE51-0CC58579EA1F Q28111717-C4F83563-BF83-4EC7-A216-2F3F5A37DF4B Q31158500-1DEA793C-3F69-4A26-B2B2-28D6672BF01D Q33629526-3CC347B7-CBA6-47A1-B887-EA435C89E017 Q34073191-51948FBC-52C8-449F-BDC1-B5D8256862C9 Q34376752-2B4E3F34-9FD8-4FD4-B5A5-3D88C7B5A50C Q34552028-0165E091-F9F9-41AB-9CEC-A54013C749D1 Q34756501-C2AF84C7-6C45-43C9-9217-9FE9C2334F16 Q34851473-699D38F1-8B9B-403F-900B-364982EC7ACC Q35762920-AE9C903E-A151-4637-AB67-42BC7C9BABF4 Q36574609-270F0E61-0F4E-4232-B157-ED733AFBB8A5 Q37047522-CF88CA42-A129-4DA9-94B6-5D4C0B529E0F Q37354812-9AF000F1-3912-42D4-943B-316FD2B087C1 Q37484842-8CF6A84B-8561-48AC-8F1D-170201ECA89F Q37576833-DE6FF914-C194-4314-B508-C01B24F46CF8 Q37616969-E43CC2A7-1E05-4FF0-80AF-1C73B1F5256F Q38132273-E6644260-399E-4B53-AE20-9AE2F24ADEF8 Q38138343-F2B27BD8-462D-4842-8EEF-7125526453F9 Q38176745-C153D8DC-842B-4B29-B770-9AB7AE7C9A82 Q38192553-7EE83EE7-32E0-44DE-902D-31F4CD04B8AF Q38198090-92FD6ACE-14EA-4B10-8494-EA49F4B030F9 Q38235809-E9A6380C-1E10-45A4-8BD7-B48050936620 Q38243693-10800363-5FB6-4C4A-837D-B82135B06E6A Q38285275-97B52B88-DB34-43BB-9D47-C9A44768089E Q38292111-B7198DDE-D6D5-4C45-8ADF-238A46BC759C Q38353491-41D167FD-ACDF-4509-880E-7243F384D94D Q38418892-5F7DA64F-377E-469C-A1AF-8D720F57ACE7 Q38611360-9438DF24-094F-4A18-8757-C146453741D5 Q38614179-C70BAB6B-363E-45BF-A94A-061BFAF1BE9A Q38668352-630527DC-6573-4762-8260-00490DAE9511 Q38779854-2A3A36E6-6E65-4DF9-BC9A-D8178F26EDE2 Q39043571-E1A12442-F928-4D27-8C5F-6DA0117F3FBE Q40116120-648749A5-3AC3-49F9-A3F2-0E9DE97B34DC Q40175407-906757E5-6728-4F0E-A0D1-4432E34519F9 Q40184103-77FB3C28-B4A4-4483-9895-3EB5492E02ED

P2860

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

http://www.wikidata.org/entity/Q37171211

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Association between the initia ...... and the risk of herpes zoster

@en

Association between the initia ...... and the risk of herpes zoster.

@nl

type

label

Association between the initia ...... and the risk of herpes zoster

@en

Association between the initia ...... and the risk of herpes zoster.

@nl

prefLabel

Association between the initia ...... and the risk of herpes zoster

@en

Association between the initia ...... and the risk of herpes zoster.

@nl

P1433

Q37171211-11B81009-984D-4297-98FF-BCDB52FEAD44

P1476

Q37171211-04444B5F-107B-4061-9592-AA8A5424407D

P2093

Q37171211-0282D9D2-D11A-4322-8A9D-C09916EB588F

Q37171211-1DD92D56-4935-4963-9F91-D3C65E0FD425

Q37171211-1DDEDF3A-B58F-4903-8E73-0E0A3832D000

Q37171211-258A90D1-0243-4A8B-B5C1-127F88AD20EF

Q37171211-4D8B2875-CB75-4AB9-A1ED-F87549BA196B

Q37171211-540822E4-F641-40ED-96D8-0F978C07A2DF

Q37171211-728DC4B5-159B-496C-95C4-94D0B5C1B673

Q37171211-88FF4001-7614-4E02-A818-70A0129E58EF

Q37171211-B046D826-3860-4100-A84E-2FC4CF325C85

Q37171211-BAD0525E-40C9-43B7-89EB-D42DE0605FB5

P2860

Q37171211-2CA75577-B7F9-4785-93F8-6687CD81320E

Q37171211-2DB5F95F-F2CB-4E77-A6A3-5A9453B657EB

Q37171211-321CE71F-9C87-40C9-B1EA-3B1885224F82

Q37171211-33EB2DC6-536E-4E5B-A27C-831842A737E8

Q37171211-354888E2-FF47-40CF-9A39-AA74406859B5

Q37171211-35870B19-0EE1-4DB3-A37F-D5C7206C4764

Q37171211-514C0735-8C27-4C2F-87AA-873A35F927DE

Q37171211-620556F2-A9A8-46DA-B9D0-908789256695

Q37171211-621827FA-41B7-477F-A13C-82BCBEBB25A2

Q37171211-65F1B8F6-217B-4460-8133-2330149B5806

P304

Q37171211-9F43389C-DAF4-4F5F-B785-3366EDFA978E

P31

Q37171211-9B7D55F9-D606-4CD0-8B11-33F5DDCBCEE1

P356

Q37171211-5E2D99F4-EDB8-4C72-A342-0B6E4B4151E7

P407

Q37171211-86960CF9-17F0-49AB-AACD-51727AB85550

P433

Q37171211-D12093E2-3DE7-468F-B0D8-8642FEE069A6

P478

Q37171211-19479C82-EF4C-4A8B-90CF-8A259EE6C263

P577

Q37171211-447C5D4A-F2FF-4838-BF40-FF6FD52D8872

P698

Q37171211-438ADBC2-7F17-4A4B-9C08-FE3AF86FC837

P932

Q37171211-B346914B-0310-4B36-B7A0-13C8BEF3921D

P356

P1433

Journal of the American Medical Association

P1476

Association between the initia ...... and the risk of herpes zoster

@en

P2093

Carlos G Grijalva

http://www.w3.org/2001/XMLSchema#string

Daniel H Solomon

http://www.w3.org/2001/XMLSchema#string

Elizabeth Delzell

http://www.w3.org/2001/XMLSchema#string

Fenglong Xie

http://www.w3.org/2001/XMLSchema#string

James D Lewis

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

John W Baddley

http://www.w3.org/2001/XMLSchema#string

Kenneth G Saag

http://www.w3.org/2001/XMLSchema#string

Kevin L Winthrop

http://www.w3.org/2001/XMLSchema#string

Lang Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The incidence of herpes zoster

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.

The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy.

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

P304

887-895

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2013.1099

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

309

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23462785

http://www.w3.org/2001/XMLSchema#string

P932

3773213

http://www.w3.org/2001/XMLSchema#string